Mahamaya Lifesciences Ltd
ncorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management.[1]
- Market Cap ₹ 423 Cr.
- Current Price ₹ 181
- High / Low ₹ 205 / 111
- Stock P/E 29.9
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 25.8 %
- ROE 34.4 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.7%
Cons
- Debtor days have increased from 52.0 to 66.6 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Part of BSE SME IPO
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 137 | 162 | 266 | |
| 128 | 148 | 241 | |
| Operating Profit | 9 | 13 | 25 |
| OPM % | 7% | 8% | 9% |
| 0 | 1 | 1 | |
| Interest | 3 | 6 | 7 |
| Depreciation | 1 | 1 | 2 |
| Profit before tax | 5 | 8 | 17 |
| Tax % | 28% | 27% | 26% |
| 4 | 5 | 13 | |
| EPS in Rs | 29.87 | 43.80 | 7.22 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 64% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 136% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 28% |
| Last Year: | 34% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|
| Equity Capital | 1 | 1 | 18 | 18 |
| Reserves | 18 | 24 | 32 | 41 |
| 24 | 55 | 58 | 68 | |
| 34 | 33 | 81 | 110 | |
| Total Liabilities | 78 | 112 | 189 | 237 |
| 21 | 21 | 27 | 31 | |
| CWIP | 2 | 3 | 4 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| 55 | 88 | 157 | 206 | |
| Total Assets | 78 | 112 | 189 | 237 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 1 | -23 | -3 | |
| -3 | -2 | -4 | |
| 3 | 24 | 8 | |
| Net Cash Flow | 1 | -1 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 25 | 64 | 67 |
| Inventory Days | 109 | 137 | 167 |
| Days Payable | 90 | 61 | 92 |
| Cash Conversion Cycle | 45 | 140 | 142 |
| Working Capital Days | 14 | 15 | 30 |
| ROCE % | 21% | 26% |
Documents
Announcements
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Appointment Of Senior Management Personnel (SMP)
17 Feb - Appointed Amarendra Mohapatra as VP-Finance & Accounts effective 17 Feb 2026; CA, 17+ years' experience.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Appointment Of Senior Management Personnel (SMP)
17 Feb - Appointed Amarendra Mohapatra as VP Finance & Accounts (SMP) effective 17-Feb-2026; CA, 17+ years.
-
Announcement Under Regulation 30 - Receiving A Prestigious Award - Company Of The Year - Medium Scale At ICSCE 2026 Dubai
22 Jan - Mahamaya Lifesciences won “Company of the Year — Medium Scale” at ICSCE, Dubai on 20 January 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
16 Jan - KFin certificate: Reg 74(5) not applicable; all shares demat, no re-materialisation requests for quarter ended 31 Dec 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
16 Jan - Reg 74(5) certificate: not applicable; all shares dematerialised; no rematerialisation requests for quarter ended 31-Dec-2025.
Annual reports
No data available.
Business Profile[1]
The company manufactures pesticide formulations and supplies bulk products to Indian agrochemical companies and multinational corporations (MNCs). It imports scientifically researched molecules, secures registrations with the Central Insecticides Board, and develops these molecules into technical-grade and value-added formulations, which are marketed to domestic manufacturers and global MNCs.